MARKET

ERAS

ERAS

Erasca, Inc.
NASDAQ
3.270
+0.080
+2.51%
After Hours: 3.270 0 0.00% 17:01 12/05 EST
OPEN
3.210
PREV CLOSE
3.190
HIGH
3.300
LOW
3.125
VOLUME
1.66M
TURNOVER
--
52 WEEK HIGH
3.375
52 WEEK LOW
1.010
MARKET CAP
927.74M
P/E (TTM)
-7.2570
1D
5D
1M
3M
1Y
5Y
1D
Gitlab, Acadia Healthcare, Box And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Benzinga · 3d ago
Weekly Report: what happened at ERAS last week (1124-1128)?
Weekly Report · 5d ago
Erasca to Present at the 8th Annual Evercore Healthcare Conference
Barchart · 11/25 08:08
Weekly Report: what happened at ERAS last week (1117-1121)?
Weekly Report · 11/24 10:24
Weekly Report: what happened at ERAS last week (1110-1114)?
Weekly Report · 11/17 10:24
Erasca Is Maintained at Buy by Guggenheim
Dow Jones · 11/14 14:29
Guggenheim Maintains Buy on Erasca, Raises Price Target to $5
Benzinga · 11/14 14:19
Erasca (ERAS) Receives a Buy from Guggenheim
TipRanks · 11/14 12:07
More
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.

Webull offers Erasca Inc stock information, including NASDAQ: ERAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ERAS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ERAS stock methods without spending real money on the virtual paper trading platform.